Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Immunomedics, Inc.
Following their original March 2019 tie-up for an oncology antibody-drug conjugate, Daiichi Sankyo and AstraZeneca have entered into a new global deal worth up to $6bn for a second novel asset from the Japanese firm, with potential in breast, lung and other cancers.
COVID-19 had a differing impact on Q2 consumer health sales for France's Boiron, the UK's Alliance Pharma and Sweden's Karo.
The latest OTC launches in the UK, including Buscomint from Sanofi, Salonpas Gel-Patch from Hisamitsu and Nailner Active Cover from Karo.
After accelerated approval in the US in April based on Phase II response rates, the company will seek full approval later this year based on a tripling of progression-free survival in a Phase III trial.
- Radiopharmaceuticals, Contrast Agents
- Large Molecule
- Other Names / Subsidiaries
- IBC Pharmaceuticals, Inc.